Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This research study is evaluating the combination of pazopanib and everolimus in patients
that have a malignancy that is metastatic or unresectable and for which standard curative or
palliative measures do not exist or are no longer effective, or metastatic or locally
advanced unresectable kidney cancer. In this research study the investigators are testing the
safety of the combination of pazopanib and everolimus and finding the appropriate doses to
use for further studies.
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital GlaxoSmithKline Novartis